Table 1.
General characteristics of the study participants, summarized by pregnancy status
| Characteristic/covariable | Nonpregnant (N = 34) | Trimester 2 (N = 87) | Trimester 3 (N = 78) |
|---|---|---|---|
| Number of observations for sulphadoxinea | 172 | 425 | 378 |
| Number of observations for pyrimethaminea | 172 | 418 | 372 |
| Mean age [years (SD)] | 23.7 (4.3) | 22.8 (3.5) | 23.5 (3.7) |
| Median gestational age at dosing [weeks (IQR)] | NA | 20 (18–21) | 28 (28–30) |
| Median body weight [kg (IQR)] | 58.0 (52.9–64.8) | 60.0 (55–66) | 63.5 (59–69.9) |
| Mean height [cm (SD)] | 163.5 (5.95) | 158.8 (5.79) | 158.3 (5.56) |
| Mean serum albumin level [g/dL (SD)] | 44.6 (2.36) | 37.4 (2.74) | 34.1 (2.89) |
| Mean serum creatinine level [µmol/L (SD)] | 71.5 (13.32) | 50.22 (8.84) | 48.0 (10.89) |
| Median ALT level [U/L (IQR)] | 3.3 (1.9–4.6) | 4.0 (3–6) | 3.9 (2.6–5.7) |
ALT alanine transaminase, IQR interquartile range, NA not applicable, SD standard deviation
aExcludes data points at time zero